Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A proprietary oral **combination dietary supplement** containing **lutein**, **zeaxanthin**, **curcuminoids** (from curcumin), and **vitamin D3**. Designed to target multifactorial dry eye disease and ocular surface inflammation, the formulation acts through several mechanisms: - **Lutein** and **zeaxanthin** are carotenoids concentrated in the macula, providing antioxidant protection against photo-oxidative stress and absorbing damaging blue light. - **Curcuminoids** (from curcumin) exhibit potent anti-inflammatory and antioxidant effects by suppressing cytokine-mediated inflammatory pathways and oxidative stress. - **Vitamin D3** offers immunomodulatory and anti-inflammatory activity, enhancing tear secretion and stabilizing tear film. The blend is micronized for enhanced bioavailability, and clinical studies demonstrate significant improvements in tear production, stability, tear osmolarity, and reduced ocular surface damage and inflammation in patients with mild to moderate dry eye symptoms. Its primary indication is **dry eye syndrome (DED)**, including improving tear volume, stabilizing tear film, and reducing ocular inflammation[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lutein + zeaxanthin + curcuminoids + vitamin D3.